A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab.

ABSTRACT: Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo-controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower incidence of non-fracture-related falls (p = 0.02). This ad hoc exploratory analysis pooled data from five placebo-controlled trials of denosumab to determine consistency across trials, if any, of the reduction of fall incidence. The analysis included trials in women with postmenopausal osteoporosis and low bone mass, men with osteoporosis, women receiving adjuvant aromatase inhibitors for breast cancer, and men receiving androgen deprivation therapy for prostate cancer. The analysis was stratified by trial, and only included data from the plac

SUBMITTER: Chotiyarnwong P 

PROVIDER: S-EPMC9328365 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature